| Q42358239 | Acute viral encephalitis |
| Q40138670 | Acyclovir A Review of its Pharmacodynamic Properties and Therapeutic Efficacy |
| Q70200384 | Acyclovir and vidarabine in the treatment of ulcerative herpes simplex keratitis |
| Q43798277 | Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients |
| Q43838626 | Acyclovir therapy for the orofacial and ganglionic HSV infection in hairless mice |
| Q35671741 | Acyclovir therapy of neonatal herpes simplex virus type 2 infections in rabbits |
| Q35671376 | Acyclovir treatment of experimental simian varicella infection of monkeys |
| Q40164352 | Acyclovir: Mechanism of Action, Pharmacokinetics, Safety and Clinical Applications |
| Q41922779 | Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections |
| Q72854158 | Antimetabolite Drug Therapy in Herpes Simplex |
| Q72660401 | Antiviral drugs |
| Q40149131 | Clinical pharmacokinetics of acyclovir |
| Q33904178 | Comparative in vitro imunotoxicology of acyclovir and other antiviral agents |
| Q28330516 | Effect of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (brovavir) on experimental infections in mice with herpes simplex virus type 1 strains of different degrees of virulence |
| Q45800074 | Effect of acyclovir on genital infection with herpes simplex virus types 1 and 2 in the guinea pig |
| Q28365880 | Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice |
| Q42928441 | Effects of prolonged cultivation in the presence of acyclovir on recovery of latent herpes simplex virus from human trigeminal ganglia |
| Q42245961 | Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine against different herpes simplex virus strains in cell culture and against experimental herpes encephalitis in mice |
| Q28366112 | Efficacy of acyclovir against mouse cytomegalovirus in vivo |
| Q34164499 | Herpes simplex virus ocular infections: current concepts of acute, latent and reactivated disease |
| Q28366044 | In vitro susceptibility of varicella-zoster virus to acyclovir |
| Q45797678 | In vivo antiviral effect of 9-(2-hydroxymethyl) guanine on experimental infection of chum salmon (Oncorhynchus keta) fry with Oncorhynchus masou virus (OMV) |
| Q42245851 | Mode of action of acyclovir triphosphate on herpesviral and cellular DNA polymerases |
| Q38161573 | New antiviral compounds |
| Q45836047 | Potential treatment of herpes simplex virus encephalitis by brain-specific delivery of trifluorothymidine using a dihydropyridine in equilibrium pyridinium salt type redox delivery system |
| Q42252469 | Relapse of herpes simplex encephalitis after acyclovir therapy |
| Q39241164 | Replication kinetics of duck enteritis virus UL16 gene in vitro |
| Q35669348 | Single-dose pharmacokinetics of acyclovir |
| Q54549070 | Strategies of drug resistance in herpes simplex |
| Q72885353 | Successful treatment with acyclovir of an immunodeficient patient infected simultaneously with multiple herpesviruses |
| Q28366946 | Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus |
| Q42926902 | Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice |
| Q35673064 | Uptake, distribution, and anabolism of acyclovir in herpes simplex virus-infected mice |
| Q40143508 | Virus drug-resistance: mechanisms and consequences |
| Q39856159 | Virus inhibition assay for measurement of acyclovir levels in human plasma and urine |